Search clinical trials for: neisseria meningitidis

Total 509 results

GlaxoSmithKline

Not yet recruiting

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Meningitis, Meningococcal

Korea, Republic of
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Gonorrhea Male

United States
Thomas Benfield

Recruiting

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV (MENPI)

Pneumococcal Infections | Hiv | Meningococcal Infections

Denmark
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Meningitis

Mali
GlaxoSmithKline

Active, not recruiting

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Infections, Meningococcal

United States, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal

United States, Australia, Argentina, Canada
Walvax Biotechnology Co., Ltd.

Completed

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Neisseria Meningitides Meningitis

Mali
Sanofi Pasteur, a Sanofi Company

Completed

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Meningitis | Meningococcal Infection

United States
Canadian Immunization Research Network
University of British Columbia; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaborators

Completed

Adolescent MenACWY Booster Study

Meningococcal Disease, Invasive

Canada
University of Adelaide

Completed

Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers (B Part Of It)

Neisseria Meningitidis

Australia
University of Oxford

Completed

Investigating Meningococcal Vaccines in Adults

Meningococcal Infections | Neisseria Meningitidis | Meningococcal Vaccines | Factor H-binding Protein, Neisseria Meningitidi

United Kingdom
Pfizer

Completed

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Meningococcal B Disease

Australia, Poland, Finland, Czechia
Serum Institute of India Pvt. Ltd.
PATH

Completed

Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Meningitis, Meningococcal

Mali
Serum Institute of India Pvt. Ltd.
PATH

Completed

Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)

Meningococcal Meningitis

Gambia, Mali
University of North Carolina, Chapel Hill
North Carolina Translational and Clinical Sciences Institute

Completed

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine (4CMenB)

Neisseria Gonorrhoeae Infection

United States
UCSF Benioff Children's Hospital Oakland
University of Massachusetts, Worcester

Completed

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Meningococcal Infections

United States
University Hospital, Montpellier

Unknown

Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection (RIPI)

Streptococcus Pyogenes Infection | Streptococcus Pneumonia | Neisseria Meningitides Meningitis

France
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
Public Health England

Completed

Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines (sched1)

Pneumococcal Infections | Meningococcal Infections

United Kingdom
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
GlaxoSmithKline

Completed

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand
GlaxoSmithKline

Completed

Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand, Philippines
GlaxoSmithKline

Completed

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Meningitis, Meningococcal

Czechia
Belfast Health and Social Care Trust
Queen's University, Belfast; Royal College of Emergency Medicine; Pediatric Emergency... and other collaborators

Completed

Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA. (PIC)

Sepsis | Meningitis, Meningococcal | Meningitis | Meningococcal Infections | Meningococcal Disease | Meningococcal Sepsis

United Kingdom
Pfizer

Completed

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

Meningococcal Infection

Mexico, Lebanon
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Infections, Meningococcal

United States
Pfizer

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Infections, Meningococcal

Finland
MCM Vaccines B.V.

Completed

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Meningococcal Disease

Chile
MCM Vaccines B.V.
Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi Company

Completed

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds

Infections, Meningococcal

Thailand, Panama, Philippines
GlaxoSmithKline

Completed

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Meningococcal Disease

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
Public Health England

Completed

Meningococcal B Vaccination in University Students (MNB3)

Neisseria Meningitidis Serogroup B

United Kingdom
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
GlaxoSmithKline

Completed

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
Public Health England

Completed

Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults

Neisseria Meningitidis
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

Infections, Meningococcal

Lebanon
GlaxoSmithKline

Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Germany, France, Canada
GlaxoSmithKline

Completed

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Infections, Meningococcal

Thailand, Estonia, Dominican Republic
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Infections, Meningococcal

United States, Canada
Merck Sharp & Dohme LLC

Completed

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Meningitis, Meningococcal | Rotavirus Infections

3

Subscribe